Maze Therapeutics, Inc. (MAZE) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Maze Therapeutics, Inc. (MAZE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Maze Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Phase 2 trial of MZE829 initiated Nov 2024; topline proof of concept data expected Q1 2026—triggered by recent clinical progress
- • Material update: Net loss $96.6M 9M 2025 vs net income $81.8M 9M 2024; accumulated deficit $455.0M due to increased R&D and operational costs
- • Regulatory risk: Potential FDA-imposed requirements for additional preclinical or clinical studies may materially increase expenses and delay approvals
- • Market risk: Dependence on timely patient enrollment and trial completion for MZE829 and MZE782 impacts near-term clinical milestones and development timelines
- • Financial risk: Cash, equivalents, and securities $383.9M as of Sept 30, 2025, sufficient for at least one year of operations but additional capital needed thereafter
Get deeper insights on Maze Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.